Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 474

1.

Cancer volume of lymph node metastasis predicts progression in prostate cancer.

Cheng L, Bergstralh EJ, Cheville JC, Slezak J, Corica FA, Zincke H, Blute ML, Bostwick DG.

Am J Surg Pathol. 1998 Dec;22(12):1491-500.

PMID:
9850175
2.

Extranodal extension in lymph node-positive prostate cancer.

Cheng L, Pisansky TM, Ramnani DM, Leibovich BC, Cheville JC, Slezak J, Bergstralh EJ, Zincke H, Bostwick DG.

Mod Pathol. 2000 Feb;13(2):113-8.

3.

Risk of prostate carcinoma death in patients with lymph node metastasis.

Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG.

Cancer. 2001 Jan 1;91(1):66-73.

PMID:
11148561
4.

Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.

Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AL, Scherer BG, Blute ML, Zincke H, Bostwick DG.

Clin Cancer Res. 1999 Oct;5(10):2820-3.

5.
6.

Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.

Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Cheng L, Bostwick DG.

J Urol. 1999 Apr;161(4):1233-7.

PMID:
10081876
7.

Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.

Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L.

J Urol. 2002 Sep;168(3):1204-11.

PMID:
12187268
8.

Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.

Boormans JL, Wildhagen MF, Bangma CH, Verhagen PC, van Leenders GJ.

BJU Int. 2008 Dec;102(11):1589-93. doi: 10.1111/j.1464-410X.2008.07904.x. Epub 2008 Aug 14.

9.

Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.

Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML.

J Urol. 2007 Sep;178(3 Pt 1):864-70; discussion 870-1. Epub 2007 Jul 16.

PMID:
17631342
10.

The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.

DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML.

J Urol. 2005 Apr;173(4):1121-5.

PMID:
15758719
11.

Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.

Da Pozzo LF, Cozzarini C, Briganti A, Suardi N, Salonia A, Bertini R, Gallina A, Bianchi M, Fantini GV, Bolognesi A, Fazio F, Montorsi F, Rigatti P.

Eur Urol. 2009 May;55(5):1003-11. doi: 10.1016/j.eururo.2009.01.046. Epub 2009 Feb 4.

PMID:
19211184
12.

Dedifferentiation in the metastatic progression of prostate carcinoma.

Cheng L, Slezak J, Bergstralh EJ, Cheville JC, Sweat S, Zincke H, Bostwick DG.

Cancer. 1999 Aug 15;86(4):657-63.

PMID:
10440694
13.

Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.

Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC.

J Urol. 2004 Nov;172(5 Pt 1):1860-4.

PMID:
15540739
15.

Correlation of margin status and extraprostatic extension with progression of prostate carcinoma.

Cheng L, Darson MF, Bergstralh EJ, Slezak J, Myers RP, Bostwick DG.

Cancer. 1999 Nov 1;86(9):1775-82.

PMID:
10547551
16.

Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases.

Fleischmann A, Schobinger S, Schumacher M, Thalmann GN, Studer UE.

Prostate. 2009 Mar 1;69(4):352-62. doi: 10.1002/pros.20889.

PMID:
19016478
17.

Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.

Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC, Skinner DG.

J Urol. 2004 Dec;172(6 Pt 1):2252-5.

PMID:
15538242
18.
19.

Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.

Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A.

BJU Int. 2011 Jun;107(11):1755-61. doi: 10.1111/j.1464-410X.2010.09730.x. Epub 2010 Oct 13.

20.

Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.

Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML.

Eur Urol. 2009 Feb;55(2):261-70. doi: 10.1016/j.eururo.2008.09.043. Epub 2008 Oct 1.

PMID:
18838212

Supplemental Content

Support Center